<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443674</url>
  </required_header>
  <id_info>
    <org_study_id>CLO-SCB-313-001</org_study_id>
    <nct_id>NCT03443674</nct_id>
  </id_info>
  <brief_title>Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies</brief_title>
  <official_title>A Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Peritoneal Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clover Biopharmaceuticals AUS Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clover Biopharmaceuticals AUS Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and PK/PD&#xD;
      of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered twice weekly for 2&#xD;
      weeks via IP bolus injection for the treatment of patients with peritoneal malignancies,&#xD;
      including but not limited to peritoneal carcinomatosis, malignant ascites, pseudomyxoma&#xD;
      peritonei, and peritoneal mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Actual">August 26, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability: Occurrence of serious adverse events (SAEs) and/or TEAEs</measure>
    <time_frame>Up to 41 days after start of treatment</time_frame>
    <description>Regardless of causality or relationship to SCB-313 graded using National Cancer Institute Common Terminology Criteria for Adverse Events Version.4.03 (NCI CTCAE v4.03).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Occurrence of binding and neutralizing anti-SCB-313 antibodies</measure>
    <time_frame>Up to 41 days after start of treatment</time_frame>
    <description>Occurrence of binding and neutralizing anti-SCB-313 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Up to 12 days after start of treatment</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax/D)</measure>
    <time_frame>Up to 12 days after start of treatment</time_frame>
    <description>Dose-normalized Cmax of SCB-313</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (tmax)</measure>
    <time_frame>Up to 12 days after start of treatment</time_frame>
    <description>Time to Cmax of SCB-313</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ([AUC]0-24)</measure>
    <time_frame>Up to 12 days after start of treatment</time_frame>
    <description>Area under SCB-313 concentration time curve from zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC0-24/D)</measure>
    <time_frame>Up to 12 days after start of treatment</time_frame>
    <description>Dose-normalized AUC0-24 of SCB-313</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics ((AUC0-last))</measure>
    <time_frame>Up to 12 days after start of treatment</time_frame>
    <description>Area under curve from time 0 on Day 1 to the last quantifiable concentration time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Ctrough)</measure>
    <time_frame>Up to 12 days after start of treatment</time_frame>
    <description>Trough concentration of SCB-313 at each predose and at 24 hours after the last dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CEA</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>Changes in serum tumor marker（CEA）</description>
  </other_outcome>
  <other_outcome>
    <measure>Caspase-cleaved cytokeratin 18 (CK-18)</measure>
    <time_frame>Up to 21 days after start of treatment</time_frame>
    <description>Changes in serum PD biomarkers</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Peritoneal Malignancies</condition>
  <arm_group>
    <arm_group_label>SCB-313</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohorts--10mg, 20mg, 40mg, 80mg, 160mg. For each cohort: administered twice weekly (eg.. Monday and Thursday or Tuesday and Friday) for 2 weeks (Days 1, 4, 8, and 11) by IP bolus injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCB-313</intervention_name>
    <description>Lyophilized powder in a single-use vial</description>
    <arm_group_label>SCB-313</arm_group_label>
    <other_name>recombinant human TRAIL-Trimer fusion protein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed peritoneal malignancies after failure or&#xD;
             refusal of all approved therapies, and no better option available in the&#xD;
             Investigator's opinion.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 2 (Patients with&#xD;
             ECOG score of 3 might be allowed to enter this trial per Investigator's judgment)&#xD;
&#xD;
          3. Life expectancy of at least 8 weeks&#xD;
&#xD;
          4. Age ≥18 years&#xD;
&#xD;
          5. Body mass index ≥17.0 kg/m2&#xD;
&#xD;
          6. Adequate hematological function, defined as:&#xD;
&#xD;
               1. Platelet count ≥ 75,000/μL&#xD;
&#xD;
               2. Prothrombin time and activated partial thromboplastin time ≤1.5 times the upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               3. Absolute neutrophil count ≥1,500/μL&#xD;
&#xD;
               4. Hemoglobin ≥8 g/dL (transfusion and erythropoietic agents are allowed. In case&#xD;
                  there is existence of active bleeding or other persistent condition of either&#xD;
                  increased destruction or impaired production of erythrocytes which may require&#xD;
                  repeated transfusion or erythropoietic treatment, the eligibility must be&#xD;
                  discussed with the Sponsor on a case-by-case basis prior to randomization)&#xD;
&#xD;
          7. Adequate renal function, defined as serum creatinine ≤2.0 times ULN and creatinine&#xD;
             clearance &gt;45 mL/minute&#xD;
&#xD;
          8. Adequate liver function, defined as:&#xD;
&#xD;
               1. Aspartate aminotransferase and alanine aminotransferase ≤3 times ULN for patients&#xD;
                  without liver metastases, or ≤5 times ULN in the presence of liver metastases&#xD;
&#xD;
               2. Bilirubin ≤1.5 times ULN, unless patient has known Gilbert's syndrome&#xD;
&#xD;
          9. Female patients of childbearing potential (excluding women who have undergone surgical&#xD;
             sterilization or menopause. Menopause is defined as the status where no menstrual&#xD;
             periods continue for 1 year or more without any other medical reasons), are eligible&#xD;
             if they have negative serum pregnancy testing within 7 days prior to first dosing and&#xD;
             are willing to use an effective method of birth control/contraception to prevent&#xD;
             pregnancy until 6 months after discontinuation of the SCB-313.&#xD;
&#xD;
        Both men and women of reproductive potential must agree to use effective contraception&#xD;
        during the study and for 6 months after discontinuation of the SCB-313.&#xD;
&#xD;
        Note: Contraceptive methods that are considered highly effective are, for example, total&#xD;
        abstinence, an intrauterine device, a double barrier method (such as condom plus diaphragm&#xD;
        with spermicide), a contraceptive implant, hormonal contraceptives (contraceptive pills,&#xD;
        implants, transdermal patches, hormonal vaginal devices, or injections with prolonged&#xD;
        release), or have a vasectomized partner with confirmed azoospermia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute or chronic infection (such as tuberculosis) requiring antiviral or intravenous&#xD;
             (IV) antibiotics within 2 weeks prior to enrollment.&#xD;
&#xD;
          2. Symptoms or signs (including laboratory tests) of clinically significant concomitant&#xD;
             hematologic, cardiovascular, pulmonary, hepatic, renal, pancreatic, or endocrine&#xD;
             diseases.&#xD;
&#xD;
          3. Residual adverse events (AEs) &gt; Grade 2 from previous treatment.&#xD;
&#xD;
          4. Evidence or suspicion of relevant psychiatric impairment including alcohol or&#xD;
             recreational drug abuse.&#xD;
&#xD;
          5. Myocardial infarction within 6 months prior to treatment, and/or prior diagnoses of&#xD;
             congestive heart failure (New York Heart Association Class III or IV), unstable&#xD;
             angina, unstable cardiac arrhythmia requiring medication, and/or long QT syndrome or&#xD;
             QT/QTc interval &gt;450 msec at baseline.&#xD;
&#xD;
          6. Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or&#xD;
             diastolic blood pressure ≥100 mmHg confirmed upon repeated measures.&#xD;
&#xD;
          7. Left ventricular ejection fraction &lt;40% as determined by echocardiography performed at&#xD;
             screening or within 90 days prior to enrollment.&#xD;
&#xD;
          8. Prior anti-tumor therapy (chemotherapy) within 2 weeks, hormone therapy or palliative&#xD;
             extra-abdominal radiotherapy within at least 1 week, or small-molecule targeted&#xD;
             therapy within 5 half-lives prior to enrollment. Prior therapy with monoclonal&#xD;
             antibody should be stopped after Investigator's judgement making sure delayed side&#xD;
             effects will not interfere with the dose limiting toxicity (DLT) evaluation period&#xD;
             after SCB-313 therapy.&#xD;
&#xD;
          9. Major surgery within 4 weeks prior to enrollment.&#xD;
&#xD;
         10. Patient with ileus within 30 days prior to screening.&#xD;
&#xD;
         11. Positive serology test for human immunodeficiency virus Type 1 and 2 or known history&#xD;
             of other immunodeficiency disease.&#xD;
&#xD;
         12. Live vaccine within 2 weeks prior to enrollment.&#xD;
&#xD;
         13. Scheduled participation in another clinical study involving an investigational product&#xD;
             or device during the course of this study.&#xD;
&#xD;
         14. Previous treatment with a TRAIL-based therapy or death receptor (DR) 4/5 agonist&#xD;
             therapy.&#xD;
&#xD;
         15. Known or suspected hypersensitivity to any component of the SCB-313.&#xD;
&#xD;
         16. Any further condition which, according to the Investigator, may result in undue risk&#xD;
             of the patient by participating in the present study.&#xD;
&#xD;
         17. Untreated central nervous system metastatic disease, leptomeningeal disease, or cord&#xD;
             compression.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Health Service</name>
      <address>
        <city>Orange</city>
        <state>New South Wales</state>
        <zip>2800</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Flynn Private Hospital</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

